Scholarlink

<p>Culpepper et al. developed a novel bioengineered yeast—<i>Saccharomyces boulardii</i>—designed to specifically target exposed fibronectin in inflamed intestinal tissues and release anti-TNF nanobodies with the goal of reducing inflammation-driven tumorigenesis in a mouse model of colorectal adenocarcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brewing a Cure: Engineering Yeast to Reduce Inflammation-Driven Tumors

  • 期刊论文

  • 发表日期：

    2025年6月26日

查看全文
  • Declan F. McCole

摘要

Culpepper et al. developed a novel bioengineered yeast—Saccharomyces boulardii—designed to specifically target exposed fibronectin in inflamed intestinal tissues and release anti-TNF nanobodies with the goal of reducing inflammation-driven tumorigenesis in a mouse model of colorectal adenocarcinoma.